1. Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using 'Low-dose' Cyclophosphamide, ATG Plus Fludarabine
- Author
-
Chayamon Takpradit, Kevin J. Curran, Andromachi Scaradavou, Julianne Ruggiero, Susan E. Prockop, Nicole Zakak, Farid Boulad, Richard J. O’Reilly, and N A Kernan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Cyclophosphamide ,Anemia ,Severity of Illness Index ,Gastroenterology ,Disease-Free Survival ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Aplastic anemia ,Child ,Survival rate ,Antilymphocyte Serum ,Bone Marrow Transplantation ,business.industry ,Graft Survival ,Anemia, Aplastic ,Hematology ,Allografts ,medicine.disease ,Tissue Donors ,Fludarabine ,Survival Rate ,Transplantation ,Regimen ,surgical procedures, operative ,Graft-versus-host disease ,Oncology ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Female ,business ,Vidarabine ,Follow-Up Studies ,030215 immunology ,medicine.drug - Abstract
Background The combination of cyclophosphamide (CY) and antithymocyte globulin (ATG) has been used as a standard conditioning regimen for matched related donor transplantation in patients with severe aplastic anemia. Procedure To decrease the regimen-related toxicity while maintaining appropriate engraftment and survival rates, fludarabine (FLU) was added to the regimen. Four pediatric patients received matched related donor bone marrow transplantation with CY (50 mg/kg×2) (instead of the 50 mg/kg×4 standard dosing), equine ATG (30 mg/kg×3), with the addition of FLU (30 mg/m×4). Graft versus host disease (GvHD) prophylaxis included a calcineurin inhibitor and methotrexate. Results No grade 4 acute toxicities occurred during the first 30 days after transplant. All patients engrafted with normalization of peripheral blood counts and transfusion independence. One patient developed grade 1 to 2 acute GvHD, followed by chronic GvHD that resolved. With a median follow-up of 41.7 months, all 4 patients are alive and transfusion free, with complete donor chimerism. This combination of a low-dose CY/ATG+FLU regimen was overall very well tolerated and contributed toward a successful outcome including engraftment, chimerism, and survival. Conclusion This small pilot study shows that this cytoreductive regimen could be considered as the standard of care for transplantation of pediatric patients with aplastic anemia from HLA-matched siblings.
- Published
- 2018